PharmaMar Has Published the Results of its Antibody Conjugate Active in Breast, Ovarian and Gastric Cancers that Express HER2
MADRID, Feb. 16, 2018 /PRNewswire/ --
PharmaMar (MCE: PHM) has announced the positive results of MI130004, a novel antibody conjugate combining trastuzumab with PM050489, a molecule of marine origin. The company has analyzed its antitumor activity in different tumor cell lines (breast, ovarian and gastric cancers) that express different levels of HER2 in both in vitro and in vivo tests.
The results published by the prestigious magazine Molecular Cancer Therapeutics, from the American Association for Cancer Research (AACR), (http://mct.aacrjournals.org/content/early/2018/02/13/1535-7163.MCT-17-0795) show that this new molecule provokes in tumors that express HER2 a longer lasting response and inhibits significantly tumor growth providing a higher median progression free survival time in comparison with trastuzumab.
MI130004 is the result of the research carried out by PharmaMar to identify and synthesize molecules of a marine origin for their use as active agents in antibody-drug conjugates, as is the case with PM050489.
As a Company, PharmaMar is positioning itself as a supplier of cytotoxic products that are necessary for companies specialized in the antibody-drug conjugate technology.
Contacts: Media Relations (+34-638-79-62-15) and Investor Relations (+34-914-44-45-00)
View original content:http://www.prnewswire.com/news-releases/pharmamar-has-published-the-results-of-its-antibody-conjugate-active-in-breast-ovarian-and-gastric-cancers-that-express-her2-300600005.html
Company Codes: Frankfurt:PMR, Madrid:PHM, OTC-PINK:PHMMF